| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
N-Acetyl-Calicheamicin (N-Acetyl-Calicheamicin γ; N-Acetyl-γ-calicheamicin), the N-acetylated analog of calicheamicin, is a novel and potent antitumor antibiotic of the enediyne class. It could be used as a potential warhead (cytotoxic DNA-binding agent) in antibody-drug-conjugation (ADC). Calicheamicins are naturally occurring hydrophobic enediyne antibiotics found in the actinomycete Micromonospora echinospora calichensis. Calicheamicins act by binding to DNA in the minor groove, and causing strand scission.
| Targets |
Anti-tumor antibiotic; ADC cytotoxin
|
|---|---|
| References | |
| Additional Infomation |
Getruzumab ozomicin (GO) is a chemotherapy drug composed of a humanized anti-CD33 antibody (hP67.6) linked to the potent enediyne antibiotic N-acetylcalic acid 1,2-dimethylhydrazine dichloride. In May 2000, the U.S. Food and Drug Administration (FDA) conditionally approved GO as monotherapy for the treatment of first-relapsed acute myeloid leukemia (AML) patients aged 60 years and older who were ineligible for conventional cytotoxic therapy. Under this indication, the complete remission (CR) rate with GO was 13%, with an additional 13% of patients achieving complete remission but with insufficient platelet recovery (CRp). The most common adverse reactions to GO are infusion-related reactions and myelosuppression. Approximately 5% of patients treated with Golov monotherapy (at a dose of 9 mg/m²) experience hepatic vein occlusion, especially before and after stem cell transplantation. Reducing the dose of Golov monotherapy or administering it in divided doses appears to be equally effective and better tolerated. Golov monotherapy has shown significant efficacy in acute promyelocytic leukemia, particularly in clearing minimal residual disease. Golov monotherapy in combination with chemotherapy shows promise as an induction therapy or post-remission treatment regimen and is currently undergoing phase III clinical trials. [1]
|
| Molecular Formula |
C57H76IN3O22S4
|
|---|---|
| Molecular Weight |
1410.38472557068
|
| Exact Mass |
1409.28
|
| Elemental Analysis |
C, 48.54; H, 5.43; I, 9.00; N, 2.98; O, 24.96; S, 9.09
|
| CAS # |
108212-76-6
|
| Related CAS # |
Calicheamicin;108212-75-5
|
| PubChem CID |
134819845
|
| Appearance |
White to off-white solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
87
|
| Complexity |
2640
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
CCN([C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C#C/C=C\C#C[C@@]4(CC(=O)C(=C3C4=CCSSSC)NC(=O)OC)O)C)NO[C@H]5C[C@@H]([C@@H]([C@H](O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)OC)O)I)C)O)O)C(=O)C
|
| InChi Key |
WPDOZYZAJKUVRZ-DPACUSKXSA-N
|
| InChi Code |
InChI=1S/C57H76IN3O22S4/c1-13-61(30(6)62)32-25-76-37(23-36(32)71-7)81-50-45(66)42(27(3)78-55(50)80-35-18-16-14-15-17-20-57(70)24-34(64)43(59-56(69)75-11)40(35)31(57)19-21-85-87-84-12)60-83-38-22-33(63)52(29(5)77-38)86-53(68)39-26(2)41(58)48(51(74-10)47(39)72-8)82-54-46(67)49(73-9)44(65)28(4)79-54/h14-15,19,27-29,32-33,35-38,42,44-46,49-50,52,54-55,60,63,65-67,70H,13,21-25H2,1-12H3,(H,59,69)/b15-14-,31-19-/t27-,28+,29-,32+,33+,35+,36+,37+,38+,42-,44+,45+,46-,49-,50-,52-,54+,55+,57+/m1/s1
|
| Chemical Name |
S-((2R,3S,4S,6S)-6-((((2R,3S,4S,5R,6R)-5-(((2S,4S,5S)-5-(N-ethylacetamido)-4-methoxytetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-(((2S,5Z,9R,13Z)-9-hydroxy-12-((methoxycarbonyl)amino)-13-(2-(methyltrisulfanyl)ethylidene)-11-oxobicyclo[7.3.1]trideca-1(12),5-dien-3,7-diyn-2-yl)oxy)-2-methyltetrahydro-2H-pyran-3-yl)amino)oxy)-4-hydroxy-2-methyltetrahydro-2H-pyran-3-yl)
4-(((2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-iodo-5,6-dimethoxy-2-methylbenzothioate
|
| Synonyms |
N-Acetyl calicheamicin; N-Acetyl-Calicheamicin; 108212-76-6; N-Acetyl-γ-calicheamicin; N-Acetylcalicheamicin γ;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~70.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL | |
| 5 mM | 0.1418 mL | 0.7090 mL | 1.4180 mL | |
| 10 mM | 0.0709 mL | 0.3545 mL | 0.7090 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
